Clinical Trials | December 07, 2025
Bayer reports promising results for low-dose pediatric MRI contrast agent
MRI is particularly valuable in pediatric care due to its non-invasive nature
MRI is particularly valuable in pediatric care due to its non-invasive nature
The topical fluralaner solution is cleared for the prevention and treatment of new world screwworm infestation
The one-time CAR T cell infusion now becomes the first and only therapy of its kind cleared for this patient population
Granules Consumer Health serves as Granules’ front-end division for OTC products in the US
Implementing PFAS testing in the early development stages allows medical device manufacturers to prepare for potential regulatory updates
The partnership aims to combine TQx’s in vivo therapeutic expertise with Kytopen’s continuous flow transfection technology
AEF0217 is a first-in-class CB1 receptor signaling-specific inhibitor
Jaypirca is the first and only FDA-approved non-covalent (reversible) BTK inhibitor
The company is excluding data from the affected sites to maintain the study's integrity
Health Canada’s approval was based on a comprehensive evaluation of analytical, nonclinical, and clinical data
Subscribe To Our Newsletter & Stay Updated
